Skip to main content
Clinical Trials/NCT05911568
NCT05911568
Recruiting
Not Applicable

Treatment With Endovascular Intervention for STroke Patients With Existing Disability

University of Cincinnati36 sites in 1 country1,060 target enrollmentNovember 16, 2023

Overview

Phase
Not Applicable
Intervention
Endovascular Stroke Treatment
Conditions
Stroke
Sponsor
University of Cincinnati
Enrollment
1060
Locations
36
Primary Endpoint
modified Rankin Scale (mRS)
Status
Recruiting
Last Updated
17 days ago

Overview

Brief Summary

TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.

Detailed Description

People with disabilities can suffer acute ischemic stroke (AIS). Endovascular clot removal is a breakthrough therapy for large vessel occlusion (LVO) AIS. Pre-stroke disabled patients were excluded from pivotal EVT stroke trials, so whether EVT is effective for those with pre-stroke disability is not known. As a result, two competing, widely-practiced, treatment paradigms have emerged based on individual practitioners' extrapolation of EVT benefits and safety from patients without a pre-stroke disability to those with disability: 1) Multimodal Medical Management (MMM; using intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol lowering medications, and other rehabilitative measures, as indicated) without EVT, and 2) EVT with the background of MMM. TESTED will enroll patients with LVO-AIS who have a pre-existing disability, defined as pre-stroke modified Rankin score (mRS) 3 and 4, at 12 geographically distinct comprehensive stroke centers serving diverse race-ethnic and socioeconomic populations. The central objective of TESTED is to determine the comparative effectiveness and safety of these two different practice paradigms.

Registry
clinicaltrials.gov
Start Date
November 16, 2023
End Date
April 15, 2028
Last Updated
17 days ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eva A. Mistry

Assistant Professor

University of Cincinnati

Eligibility Criteria

Inclusion Criteria

  • Adult patients (≥18 years)
  • Moderate-to-severe pre-stroke functional disability, defined as mRS 3-4, for at least 3 months prior to stroke onset
  • Presenting to study hospital within 24 hours of last known well time
  • Diagnosis of acute ischemic stroke
  • Intracranial causative occlusion of the internal carotid artery or the M1 or dominant M2 segments of the middle cerebral artery visualized on the baseline CT(or MR) angiogram
  • Presenting CT Alberta Stroke Program Early CT (ASPECT) score ≥3 or MRI ASPECT score ≥4
  • Presenting NIH Stroke Scale score ≥6
  • Informed consent from patient if competent or from legally authorized representative

Exclusion Criteria

  • Known diagnosis of a terminal cancer or terminal illness at the time of stroke
  • Assessment of pre-stroke functional status cannot be performed during the hospital stay
  • Pre-stroke disability deemed temporary in the investigator's opinion (for example, recovering from a general medical illness or traumatic bodily injury)

Arms & Interventions

Stroke patients with moderate-to-severe pre-stroke disability

Patients with pre-stroke modified Rankin scale score 3 or 4, presenting with a anterior circulation large vessel occlusion stroke within 24 hours of last known well

Intervention: Endovascular Stroke Treatment

Stroke patients with moderate-to-severe pre-stroke disability

Patients with pre-stroke modified Rankin scale score 3 or 4, presenting with a anterior circulation large vessel occlusion stroke within 24 hours of last known well

Intervention: Medical Management

Outcomes

Primary Outcomes

modified Rankin Scale (mRS)

Time Frame: 90 (±14) days after treatment initiation

Score of 0-3, 4, 5 or 6 on the modified Rankin Scale (mRS) (Note: mRS range: 0 (no residual symptoms) to 6 (death)

Secondary Outcomes

  • Disability-weighted (or utility-weighted) mRS(90 (±14) days after treatment initiation)
  • EQ-5D-5L(90 (±14) days after treatment initiation)
  • Return to the pre-stroke mRS level(90 (±14) days after treatment initiation)
  • Academic Medical Center - Linear Disability Scale (ALDS)(90 (±14) days after treatment initiation)

Study Sites (36)

Loading locations...

Similar Trials